BiotoxtechCo (086040): Korean Health Care stock

What the company does

BiotoxtechCo is a South Korean biotech company focused on toxicology testing and safety evaluation services, helping pharmaceutical and chemical developers assess whether their compounds are safe before clinical or commercial use.

It supplies these contract research and testing services to drug developers, chemical manufacturers, and other life-sciences clients. The company is listed on KOSDAQ, South Korea's tech and small-cap exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$34.1M

▲ +13.7% YoY

Operating profit · FY2025

−US$3.5M

Loss narrowed

Net income · FY2025

−US$1.1M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$23.6M(₩32.6B)	US$30M(₩41.3B)	US$34.1M(₩47B)
Operating profit	−US$5.9M(−₩8.2B)	−US$6.4M(−₩8.9B)	−US$3.5M(−₩4.8B)
Net income	−US$6.5M(−₩9B)	−US$9.2M(−₩12.7B)	−US$1.1M(−₩1.6B)

Revenue

FY2023US$23.6M
FY2024US$30M
FY2025US$34.1M

Operating profit

FY2023−US$5.9M
FY2024−US$6.4M
FY2025−US$3.5M

Net income

FY2023−US$6.5M
FY2024−US$9.2M
FY2025−US$1.1M

Key ratios (FY2025)

ROE

-4.9%

Debt/Eq

312.2%

Op. margin

-10.2%

Net margin

-3.4%

Rev. YoY

▲ +13.7%

Filings

All disclosures · English when translated

Price charts coming soon

Interactive price history isn't here yet. Would you use it?